<SEC-DOCUMENT>0001193125-21-021511.txt : 20210129
<SEC-HEADER>0001193125-21-021511.hdr.sgml : 20210129
<ACCEPTANCE-DATETIME>20210129060851
ACCESSION NUMBER:		0001193125-21-021511
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210129
FILED AS OF DATE:		20210129
DATE AS OF CHANGE:		20210129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		21567936

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d125199d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of January, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia
Therapeutics Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> <B></B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 29 January 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g125199g45f49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">29&nbsp;January
2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 29</B><B></B><B>&nbsp;January 2021</B> &#150; Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology
company, is pleased to provide an update on the ongoing development of its product candidates for the quarter ending 31&nbsp;December 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Points
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GBM AGILE pivotal study opened to recruitment for the paxalisib arm, placing the drug on a direct path to
commercialisation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completion of an AU$ 25&nbsp;million financing round in October 2020 leaves the company well-funded to commence
GBM AGILE pivotal study; initial <FONT STYLE="white-space:nowrap">one-off</FONT> <FONT STYLE="white-space:nowrap">start-up</FONT> fee of US$ 5&nbsp;million paid on execution </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New clinical collaboration launched with Pacific Pediatric Neuro-Oncology Consortium (PNOC) to investigate
paxalisib as combination therapy in DIPG </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim analysis of paxalisib phase II study in glioblastoma presented at Society for Neuro-Oncology (SNO) Annual
Meeting, directionally confirming earlier results </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim analysis of paxalisib phase I study in DIPG presented at SNO Annual Meeting, showing favourable safety
and tolerability </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Final <FONT STYLE="white-space:nowrap">top-line</FONT> data from Cantrixil phase I study in ovarian cancer
released; definitive study publication in draft </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia CEO, Dr James Garner, commented, &#147;the December quarter has been defined by
two critical achievements: a financing round that will substantially fund the GBM AGILE pivotal study for paxalisib, and the subsequent commencement of recruitment to that study. We are now, in common parlance, a &#145;phase III company&#146;, with
our lead program on a direct path to a potential FDA approval, and that elevation in status is beginning to be reflected in a much broader and deeper level of investor engagement.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commencement of GBM AGILE Pivotal Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
16&nbsp;October 2020, immediately following a successful $25&nbsp;million financing round, Kazia executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to execute the paxalisib arm of the GBM AGILE pivotal study
(NCT03970447). Positive data from this study is expected to support the registration of paxalisib as a new therapeutic for glioblastoma. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GBM AGILE has been established by leading clinicians and researchers in the glioblastoma field to expedite
the approval of promising new therapies for the disease. It is an adaptive study, in which the number of patients recruited is constantly adjusted according to emerging data. Through this and other efficiencies, GBM AGILE lowers the cost of
developing a new drug in glioblastoma by a very substantial margin, while still providing gold-standard clinical data to support registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GBM AGILE
is currently active at 35 sites in the United States and will shortly be opening in Canada. Expansion to EU and China is expected during CY2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Successful Capital Raise Provides AU$ 25 Million in New Funding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted in the company&#146;s previous Appendix 4C, on 1&nbsp;October 2020, Kazia launched a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-three</FONT></FONT> accelerated <FONT STYLE="white-space:nowrap">non-renounceable</FONT> entitlement offer to raise approximately $25&nbsp;million, before fees. The
transaction was fully underwritten by Bell Potter Securities Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accelerated institutional component closed on 2&nbsp;October 2020, raising
approximately $16.4&nbsp;million from institutional investors, representing approximately a 70% <FONT STYLE="white-space:nowrap">take-up.</FONT> The retail component closed on 20&nbsp;October 2020, raising a further $8.8&nbsp;million, with
approximately 32% <FONT STYLE="white-space:nowrap">take-up.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This financing leaves the company well-funded to implement the GBM AGILE pivotal
study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Study in DIPG </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On 10&nbsp;December 2020,
Kazia announced that it had signed a Letter of Intent (LOI) with the Pacific Pediatric Neuro-Oncology Consortium (PNOC) to include paxalisib in a new clinical trial of multiple therapies in combination for patients with DIPG and other diffuse
midline gliomas (DMGs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PNOC study will also include <FONT STYLE="white-space:nowrap">ONC-201</FONT> (Oncoceutics, Inc) and panobinostat (SecuraBio,
Inc) and will explore treatments in various combinations using an adaptive design. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of note, the PNOC study has built off an extensive body of laboratory
research undertaken by Associate Professor Matt Dun at the Hunter Medical Research Institute in Newcastle, NSW. The Dun laboratory research is expected to be published in a peer-reviewed academic journal during 1H CY2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia&#146;s participation in the PNOC study incurs no direct cost to Kazia, beyond provision of study drug and administrative support. Implementation is
subject to approval by FDA and relevant institutional review boards, and to execution of a definitive agreement between Kazia and the University of California, San Francisco (UCSF) on behalf of PNOC. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interim Data from Phase II Study in Glioblastoma&nbsp;&amp; Phase I Study in DIPG </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia reported new interim data from the ongoing phase II study of paxalisib in glioblastoma (NCT03522298) at the Society for Neuro-Oncology (SNO) Annual
Meeting in November 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim analysis of all patients in the study (n=30) showed a progression-free survival (PFS) of 8.4 months, and an overall
survival (OS) of 17.5 months. These numbers compare favourably with the historical control: corresponding figures of 5.3 months and 12.7 months, respectively, are reported with temozolomide, the only
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> standard of care in newly diagnosed glioblastoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the same meeting, Dr Chris Tinkle and
colleagues gave an oral presentation on interim data from their ongoing phase I study of paxalisib as monotherapy in patients with DIPG and DMGs (NCT03696355). The study had recruited 27 patients and reported generally favourable safety and
tolerability with paxalisib, having determined a maximum tolerated dose (MTD) in children of 27 mg/m<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was not, at the time of analysis, a clear signal of efficacy, which was unsurprising given that the primary focus of the study was safety and
tolerability. However, the authors reported a progression-free survival at 6 months (PFS6) of 96%, which compares favourably to an historical control of 58%. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Final <FONT STYLE="white-space:nowrap">Top-Line</FONT> Data from Cantrixil Phase I Study in Ovarian Cancer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On 9&nbsp;December 2020, Kazia reported <FONT STYLE="white-space:nowrap">top-line</FONT> final data from the completed phase I study of Cantrixil <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(TRX-E-002-1)</FONT></FONT></FONT> in advanced ovarian cancer. In total, 25 patients were recruited at hospitals in the United States and Australia. An MTD
of 5 mg/kg was determined, with the key side effects being abdominal pain and gastro-intestinal symptoms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among 16 evaluable patients, one patient
demonstrated a complete response (CR) according to RECIST criteria, and two patients demonstrated partial responses (PRs), making an overall response rate (ORR) of 19%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is currently working alongside the investigators to produce a manuscript for submission to a peer-reviewed academic journal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Receipt of $1.02&nbsp;million R&amp;D Tax Rebate </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
14&nbsp;December 2020, Kazia received $1.02&nbsp;million via the Australian R&amp;D Tax Rebate scheme. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Completion of Unmarketable Parcel Share Sale
Facility </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As announced to ASX on 2&nbsp;November 2020, Kazia launched an unmarketable parcel share sale facility in which parcels of less than AU$ 500
in value could be resumed and <FONT STYLE="white-space:nowrap">re-sold,</FONT> with the benefits accruing to the holder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This facility closed as planned on 18&nbsp;December 2020, with 243,784 shares being purchased from
shareholders and sold on market for an average price of $1.37 per share. The proceeds from the sale of these shares is to be distributed to those shareholders during the first week of February 2021. As a result of the facility, a total of 1,860
shareholders have left the register, and a number of other shareholders took the opportunity to consolidate their holdings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company has no revisions to its prior guidance concerning
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> but envisages a systematic review with investigators during 1Q CY2021. At present, there is limited operational impact, but Kazia continues to monitor the situation closely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Broad Clinical Program Ongoing </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Sponsor</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">II</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Glioblastoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCT03522298</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Global Coalition for Adaptive Research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">II&nbsp;/&nbsp;III</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Glioblastoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCT03970447</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alliance for Clinical Trials in Oncology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">II</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brain metastases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCT03994796</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dana-Farber Cancer Institute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">II</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Breast cancer brain metastases</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>with Herceptin</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCT03765983</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dana-Farber Cancer Institute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">II</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Primary CNS lymphoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TBD</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pacific Pediatric Neuro-Oncology Consortium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">N/A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DIPG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TBD</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">St Jude Children&#146;s Research Hospital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">I</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DIPG (childhood brain cancer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCT03696355</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Memorial Sloan Kettering Cancer Center</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">I</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brain metastases</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>with radiotherapy</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCT04192981</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Update </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
noted in the accompanying Appendix 4C, the company&#146;s cash position as at 31&nbsp;December 2020 was AU$ 19.366&nbsp;million. The company invested AU$10&nbsp;million in research and development activities during 2Q FY2021, including an initial <FONT
STYLE="white-space:nowrap">one-off</FONT> fee of US$ 5M (~AU$ 6.5M) to commence the GBM AGILE pivotal study, and incurred G&amp;A expenses of AU$ 0.5&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of cash at 31&nbsp;December 2020 and expenditure during the quarter, the Appendix 4C reflects 1.92 quarters of available funding. However, as
noted above, the company incurred substantial <FONT STYLE="white-space:nowrap">one-off</FONT> payments in 2Q FY2021 associated with commencement of the GBM AGILE pivotal study for paxalisib. As a result, expenditure in this quarter is
unrepresentative of ongoing spend. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes
two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is
paxalisib (formerly <FONT STYLE="white-space:nowrap">GDC-0084),</FONT> a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in
adults. Licensed from Genentech in late 2016, paxalisib entered GBM AGILE, a pivotal study in glioblastoma, in October 2020. Seven additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for
glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August
2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TRX-E-002-1</FONT></FONT></FONT> (Cantrixil) is
a third generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TRX-E-002-1</FONT></FONT></FONT> has completed a phase I clinical trial in Australia and the United States. Cantrixil was granted orphan designation
for ovarian cancer by the US FDA in April 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Rule 4.7B </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix 4C </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Quarterly
cash flow report for entities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>subject to Listing Rule 4.7B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Name of entity </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ABN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Quarter ended (&#147;current quarter&#148;)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">37 063 259 754</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">December 2020</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Consolidated statement of cash flows</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Current&nbsp;quarter<BR>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;to&nbsp;date<BR>(6 months)<BR>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>1.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;Cash flows from operating activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Receipts from customers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Payments for</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(a)&#8201;&#8202;research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(b)&#8201;&#8202;product manufacturing and operating costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(c)&#8201;&#8202;advertising and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(d)&#8201;&#8202;leased assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(e)&#8201;&#8202;staff costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;(f)&#8201;&#8201;administration and corporate costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Dividends received<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>(see note&nbsp;3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Interest received</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Interest and other costs of finance paid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Income taxes paid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Government grants and tax incentives</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;Other (provide details if material)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>1.9</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;Net cash from / (used in) operating activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,036</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12,269</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; ">
<TD COLSPAN="10" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rules Appendix 4C (17/07/20)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+ See chapter 19 of the ASX Listing Rules for defined terms.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 1</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix 4C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Quarterly cash flow report for entities subject to Listing Rule 4.7B </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Consolidated statement of cash flows</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Current&nbsp;quarter<BR>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;to&nbsp;date</B><br><B>(6&nbsp;months)<BR>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>2.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Cash flows from investing activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Payments to acquire or for:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&#8194;&#8201;&#8202;entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&#8194;&#8201;&#8202;businesses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(c)&#8194;&#8201;&#8202;property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(d)&#8194;&#8201;&#8202;investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(e)&#8194;&#8201;&#8202;intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(f)&#8194;&#8201;&#8201;other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Proceeds from disposal of:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&#8194;&#8201;&#8202;entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&#8194;&#8201;&#8202;businesses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(c)&#8194;&#8201;&#8202;property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(d)&#8194;&#8201;&#8202;investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(e)&#8194;&#8201;&#8202;intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(f)&#8194;&#8201;&#8201;other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cash flows from loans to other entities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dividends received (see note&nbsp;3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Other (provide details if material)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>2.6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Net cash from / (used in) investing activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>3.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Cash flows from financing activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Proceeds from issues of equity securities (excluding convertible debt securities)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Proceeds from issue of convertible debt securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Proceeds from exercise of options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Transaction costs related to issues of equity securities or convertible debt securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Proceeds from borrowings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Repayment of borrowings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Transaction costs related to loans and borrowings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dividends paid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Other (provide details if material)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>3.10</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Net cash from / (used in) financing activities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,597</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,609</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rules Appendix 4C (17/07/20)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+ See chapter 19 of the ASX Listing Rules for defined terms.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 2</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix 4C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Quarterly cash flow report for entities subject to Listing Rule 4.7B </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Consolidated statement of cash flows</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Current&nbsp;quarter<BR>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;to&nbsp;date</B><br><B>(6&nbsp;months)<BR>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>4.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Net increase / (decrease) in cash and cash equivalents for the period</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cash and cash equivalents at beginning of period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Net cash from / (used in) operating activities (item&nbsp;1.9 above)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12.269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Net cash from / (used in) investing activities (item&nbsp;2.6 above)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Net cash from / (used in) financing activities (item&nbsp;3.10 above)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Effect of movement in exchange rates on cash held</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>4.6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Cash and cash equivalents at end of period</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,366</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,366</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>5.</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>Reconciliation of cash and cash equivalents </B><B><BR></B>at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Current&nbsp;quarter<BR>$A&#146;000</B></TD>
<TD NOWRAP VALIGN="bottom"><B><BR>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Previous&nbsp;quarter<BR>$A&#146;000</B></TD>
<TD NOWRAP VALIGN="bottom"><B><BR>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bank balances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Call deposits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bank overdrafts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Other (provide details)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>5.5</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Cash and cash equivalents at end of quarter (should equal item&nbsp;4.6 above)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,366</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,543</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>6.</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>Payments to related parties of the entity and their associates</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;<BR></B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Current&nbsp;quarter<BR>$A&#146;000</B></TD>
<TD NOWRAP VALIGN="bottom"><B><BR>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aggregate amount of payments to related parties and their associates included in item&nbsp;1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aggregate amount of payments to related parties and their associates included in item&nbsp;2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="10"><I>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</I></TD>
<TD VALIGN="top"><I>&nbsp; </I>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rules Appendix 4C (17/07/20)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+ See chapter 19 of the ASX Listing Rules for defined terms.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix 4C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Quarterly cash flow report for entities subject to Listing Rule 4.7B </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt"><B>7.</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financing facilities<BR></B><I>Note: the term &#147;facility&#146; includes all forms of financing arrangements available to
the<BR>entity.</I><B></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Add notes as necessary for an understanding of the sources of finance available to the<BR>entity.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;facility<BR>amount at</B><br><B>quarter&nbsp;end<BR>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B><br><B>drawn&nbsp;at</B><br><B>quarter&nbsp;end<BR>$A&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Loan facilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Credit standby arrangements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Other (please specify)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Total financing facilities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Unused financing facilities available at quarter end</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="4" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="8">Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into
or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>8.</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>Estimated cash available for future operating activities</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>$A&#146;000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Net cash from / (used in) operating activities (item&nbsp;1.9)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cash and cash equivalents at quarter end (item&nbsp;4.6)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Unused finance facilities available at quarter end (item&nbsp;7.5)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Total available funding (item&nbsp;8.2 + item&nbsp;8.3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Estimated quarters of funding available (item&nbsp;8.4 divided by item&nbsp;8.1)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="6"><I>Note: if the entity has reported positive net operating cash flows in item&nbsp;1.9, answer item&nbsp;8.5 as &#147;N/A&#148;. Otherwise, a figure for the estimated quarters of funding available must be included in
item&nbsp;8.5.</I></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">If item&nbsp;8.5 is less than 2&nbsp;quarters, please provide answers to the following questions:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">8.6.1&#8194;&#8201;&#8201;Does the entity expect that it will continue to have the
current level of net operating cash flows for the time being and, if not, why not?</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&#8194;&#8201;&#8201;&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="79%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-2.00em; font-size:10pt; font-family:Times New Roman">Answer: Not at
all &#150; the December quarter saw the outflow of a prepayment of USD5m for the start of the GBM Agile trial, as well as significant start up expenses associated with that trial. Adjusting only for the deposit, the cash outflow would have been
approx. AUD7m lower and the cash balance approx. AUD7m higher, yielding a result of 7 quarters of cash available.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">8.6.2&#8194;&#8201;&#8201;Has the entity taken any steps, or does it propose to take any steps, to raise further cash
to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="79%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-2.00em; font-size:10pt; font-family:Times New Roman">Answer: Please
note the response to question 8.6.1. The Company believes it has sufficient cash to fund the operations for the remainder of calendar 2021.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">8.6.3&#8194;&#8201;&#8201;Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-2.00em; font-size:10pt; font-family:Times New Roman">Answer: Yes as described above</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><I>Note: where item&nbsp;8.5 is less than 2&nbsp;quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rules Appendix 4C (17/07/20)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+ See chapter 19 of the ASX Listing Rules for defined terms.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 4</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix 4C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Quarterly cash flow report for entities subject to Listing Rule 4.7B </B></P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compliance statement </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This statement has been prepared in accordance with accounting standards and policies which comply with Listing
Rule 19.11A. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This statement gives a true and fair view of the matters disclosed. </P></TD></TR></TABLE>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 January 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Authorised&nbsp;by:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">Board of Dirctors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Name&nbsp;of&nbsp;body&nbsp;or&nbsp;officer&nbsp;authorising&nbsp;release&nbsp;&#150;&nbsp;see&nbsp;note&nbsp;4)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notes </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This quarterly cash flow report and the accompanying activity report provide a basis for informing the market
about the entity&#146;s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing
Rules is encouraged to do so. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the
definitions in, and provisions of, <I>AASB 107: Statement of Cash Flows </I>apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dividends received may be classified either as cash flows from operating activities or cash flows from
investing activities, depending on the accounting policy of the entity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this report has been authorised for release to the market by your board of directors, you can insert here:
&#147;By the board&#148;. If it has been authorised for release to the market by a committee of your board of directors, you can insert here: &#147;By the [<I>name of board committee</I> &#150; <I>eg Audit and Risk Committee</I>]&#148;. If it has
been authorised for release to the market by a disclosure committee, you can insert here: &#147;By the Disclosure Committee&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this report has been authorised for release to the market by your board of directors and you wish to hold
yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council&#146;s <I>Corporate Governance Principles and Recommendations</I>, the board should have received a declaration from its CEO and CFO that, in their opinion,
the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the
basis of a sound system of risk management and internal control which is operating effectively. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX Listing Rules Appendix 4C (17/07/20)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+ See chapter 19 of the ASX Listing Rules for defined terms.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-TOP:1px solid #000000">Page 5</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g125199g45f49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g125199g45f49.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( (X#- ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\)P*3<*24XC;Z5^:_Q<_X.2O
M_P (OC%XR\&W'PQ\:7UUX+\0:CX>GNH;VT2*YELKJ6V>1 S;@K-$6 /.".^:
MUI49U':"N9U*T*:O-V/TIW"C<*_+?_B*,\!?]$G\=_\ @PLO_BZ/^(HOP#_T
M2GQY_P"#"Q_^+K7ZCB/Y&<_UZA_.C]2-PHW"ORW_ .(HOP#_ -$I\>?^!]C_
M /%T?\11G@+_ *)/X[_\&%E_\71]1Q'\C#Z]0_G1^I&X4;A7Y;_\11G@(_\
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M1G@'_HE'CS_P86/_ ,71]1Q'\C#Z]0_G7XGZD;A1N%?EO_Q%%^ ?^B4^//\
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M'V/_ ,71_P 11?@'_HE/CS_P86/_ ,73^HXC^1C^O4/YU^)^I&X4;A7Y;_\
M$49X"_Z)/X[_ /!A9?\ Q='_ !%&> 3_ ,TH\>?^#"Q_^+I?4<1_(Q?7J'\Z
M_$_4C<*-PK\M_P#B*+\ _P#1*?'G_@?8_P#Q='_$49X"_P"B3^.__!A9?_%T
M?4<1_(P^O4/YU^)^I&X4;A7Y;_\ $49X"_Z)/X[_ /!A9?\ Q='_ !%%^ ?^
MB4^//_ ^Q_\ BZ/J.(_D8?7J'\Z_$_4C<*-PK\M_^(HOP#_T2GQY_P"#"Q_^
M+H_XBC/ 7_1)_'?_ (,++_XNCZCB/Y&'UZA_.OQ/U(W"C<*_+?\ XBB_ /\
MT2GQY_X,+'_XNC_B*+\ _P#1*?'G_@?8_P#Q='U'$?R,/KU#^='ZD;A1N%?E
MO_Q%&> O^B3^._\ P867_P 71_Q%&> O^B4>._\ P86/_P 71]1Q'\C#Z]0_
MG7XGZD;A1N%?EO\ \11?@'_HE/CS_P #['_XNC_B*,\!#_FE'CS_ ,&%C_\
M%T?4<1_(P^O4/YT?J1N%&X5^6_\ Q%&> O\ HD_CO_P867_Q='_$47X!_P"B
M4^//_!A8_P#Q='U'$?R,/KU#^=?B?J1N%&X5^6__ !%%^ ?^B4^//_ ^Q_\
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MC/ 7_1*/'G_@PL?_ (NCZCB/Y&'UZA_.OQ/U(W"C<*_+?_B*+\ _]$I\>?\
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MP%_T2?QW_P"#"R_^+H^HXC^1B^O4/YU^)^I&X4;A7Y;_ /$47X!_Z)3X\_\
M ^Q_^+H_XBB_ /\ T2GQY_X,+'_XNG]1Q'\C']>H?SK\3]2-PHW"ORW_ .(H
MSP%_T2?QW_X,++_XNC_B*+\ _P#1*?'G_@PL?_BZ7U'$?R,7UZA_.OQ/U(W"
MC<*_+?\ XBB_ /\ T2GQY_X'V/\ \71_Q%&> O\ HE'CO_P86/\ \71]1Q'\
MC#Z]0_G7XGZD;A1N%?EO_P 11G@+_HE'CO\ \&%C_P#%T?\ $47X!_Z)3X\_
M\#['_P"+H^HXC^1A]>H?SH_4C<*-PK\M_P#B*,\ C_FE'CS_ ,&%C_\ %T?\
M11G@+_HD_CO_ ,&%E_\ %T?4<1_(P^O4/YU^)^I&X4;A7Y;_ /$47X!_Z)3X
M\_\ !A8__%T?\11?@'_HE/CS_P #['_XNCZCB/Y&/Z]0_G1^I&X4;A7Y;_\
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M-'_?- !C_=HQ_NT?]\T?]\T &/\ =HQ_NT?]\T?]\T &/]VC'^[1_P!\T?\
M?- !C_=HQ_NT?]\T?]\T &/]VC'^[1_WS1_WS0 8_P!VC'^[1_WS1_WS0 8_
MW:,?[M'_ 'S1_P!\T &/]VC'^[1_WS1_WS0 8_W:,?[M'_?-'_?- !C_ ':,
M?[M'_?-'_?- !C_=HQ_NT?\ ?-'_ 'S0 8_W:,?[M'_?-'_?- !C_=HQ_NT?
M]\T?]\T &/\ =HQ_NT?]\T?]\T &/]VC'^[1_P!\T?\ ?- !C_=HQ_NT?]\T
M?]\T &/]VC'^[1_WS1_WS0 8_P!VC'^[1_WS1_WS0 8_W:,?[M'_ 'S1_P!\
MT &/]VC'^[1_WS1_WS0 8_W:,?[M'_?-'_?- !C_ ':,?[M'_?-'_?- !C_=
MHQ_NT?\ ?-'_ 'S0 8_W:,?[M'_?-'_?- !C_=HQ_NT?]\T?]\T &/\ =HQ_
MNT?]\T?]\T &/]VC'^[1_P!\T?\ ?- !C_=HQ_NT?]\T?]\T &/]VC'^[1_W
MS1_WS0 8_P!VC'^[1_WS1_WS0 ZV'^D1_=^]VK^E3_@CU_RBN_9[_P"Q!TC_
M -)8Z_FKM_\ CXC^[]ZOZ5/^"/7_ "BN_9[_ .Q!TC_TECKQLZ_AQ]?T1ZN3
M_'+T_5GTA1117SA[XV3_ %;?2OY8?VSSC]M[X[?=_P"2F>*.O_89O*_J>D_U
M;?2OY8?VSSC]M[X[<_\ -3/%'_IYO*]C)?XK]/U/'SC^''U/.=W^[1N_W:-W
M^T/RHW?[0_*OI#PPW?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\
M=HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0
M_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]
MVC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#
M\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W
M:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\
M=HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0
M_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]
MVC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#
M\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W
M:-W^T/RHW?[0_*@ W?[M&[_=HW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M
M#\J #=_NT;O]VC=_M#\J-W^T/RH -W^[1N_W:-W^T/RHW?[0_*@ W?[M&[_=
MHW?[0_*C=_M#\J #=_NT;O\ =HW?[0_*C=_M#\J #=_NT;O]VC=_M#\J-W^T
M/RH -W^[1N_W:-W^T/RHW?[0_*@!UL?](C^[][M7]*G_  1Z_P"45W[/?_8@
MZ1_Z2QU_-7;G-Q'R/O5_2I_P1Z_Y17?L]_\ 8@Z1_P"DL=>-G7\./K^B/6RC
MXY>GZL^D****^</>&R?ZMOI7\L/[9YQ^V]\=N?\ FIGBCM_U&;NOZGI/]6WT
MK^6']L\X_;>^.W/_ #4SQ1V_ZC-Y7LY+_%?I^IX^<?PX^IYSN_VOTHW?[7Z4
M;O\ :_2C=_M?I7T9X8;O]K]*-W^U^E&[_:_2C=_M?I0 ;O\ :_2C=_M?I06]
M_P!*]NT[]A_4-0_X)XZA^T"OB73_ "K#4VB_X1EK<&ZETX:A_9C:CYBR;MBW
M@*&(1Y*JS;^1B)5(QMS/?0J,7+X?4\1W?[7Z4;O]K]*]R^*?[%EI\&OV:M$\
M;ZM\1]"7Q5KWA#2O'FG^$'LGBN-2TF]E,:+973LL5W?1 ;Y;95QM/$FTAJT_
MVC/^">M_\ /!"^(H?%2^)M)\4:WI.C_#633]+8R_$>*^LH[QKNWA\TR1Q0K<
M16^%$IDG94#*<9S6*I-V3-/J]1=#YZW?[7Z4;N>M>H?LY_LJ:]^TSI'Q(_X1
M\S2>(OA_9:;-;:.MH9)-9NK[41816V[<OV?#X=G<-M (*CDKW?PT_8F\#_$3
M]KC5/@Y;_&2:;7H=;A\/:+=Z=X(N=2A\077E.U\%\NX BAM&20&9CB1$,J;5
MXISQ$(WOTW%&A.232WV/G3=S][]*-W^U^E>__L^_L&_\-*ZG\7E\.^.-/DT_
MX=S7-GX9NDTYYQ\0[I(=1N;>WM,2 1F6TL#,&;?@2J<$Y)\;^&G@L?$W1/&5
MY#??91X2\+-XF4&$O]L OK"U\GJ-G_'[OW8/,6W&&R"->#Z[?KL'L)JUUO\
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M?I1N_P!K]*-W^U^E&[_:_2@ W?[7Z4;O]K]*-W^U^E&[_:_2@ W?[7Z4;O\
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M1#ACDAB-PKTJ.7WA"M5DHP<K/NO.Q\WBL_:KU<%A*;G5C#FC?2+?:YX+XA\
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M"VT'@MC )&2,C/0?\,]_$3_HG_CS_P )V]_^-5,IQ3LV-1;V.1W?[7Z4;O\
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M_+#^V?\ \GO?';[W_)3/%'_IYO*]C)?XK]/U/'SC^''U/.<^[?E1GW;\J/\
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MY49]V_*C_OJC_OJ@ S[M^5&?=ORH_P"^J/\ OJ@ S[M^5&?=ORH_[ZH_[ZH
M,^[?E1GW;\J/^^J/^^J #/NWY49]V_*C_OJC_OJ@ S[M^5&?=ORH_P"^J/\
MOJ@ S[M^5&?=ORH_[ZH_[ZH 3<2?XORKUO\ 8L^*&B_!3XT6GB+Q-:W<>DW5
MM-90:BEOYRV4YP=Z[?O< J<9(#' ->0SKOC9<D;ACDXK[ ^(W[8_P[\1?L=7
M'A6SAN&U*ZT9-,AT4VK>597"QA?.+CY-JM^\R#N.>E>EEL8J;K.:BX*ZOU\C
MY_B*I5=&.%A1E4C5?))QTY4^M_\ /]3R?]N;XT>'?C7\6=/U#PT))HM-L6MK
MF_DB>%KV4N&5L, WR 8!8 _,>U4/AG^S1#XX^%#:\^K/;74@E:WMUC4P1A"0
M?-;JN[!SC&!@G.:SOV:(_";>)M03Q4NGM_HX^P_;O]07S\^02%+XZ9]ZP_B+
MXGATSQ5X@L/#.I7D'A>\GW?9X;F1;6;@;R%R!MW9QD<CL17QN;9EC<PQL\+A
M;TIIQFY\ONM/5Q7]=-=S]<X1X?R7(<FI9IFJABJ,U.E&DJC56,DM)RM;16>G
M2\>NW<_"N#X<7/P$N)-8;3AK+1RFX$K;;M7.3'Y*YW,-NW&WC.<@U0\ ?LSQ
M^./@W'XDFUJ2+4+J%[F&(JGEQK&64K(W8DH3[ CUKG-!_9[\=>*/"G]N:=X3
MUZ^TD+O6>&WSYBX^]&APSKQU48..,USNF^)]0LM+DTO^T-2ATFZD N[.&1U2
M09PV5R.0,@C YR#TKGQ&0X^BIU</B)1<Y\[YE?W5O&*Z)]/N['1EO'628QT<
M/F6!I5/8T94E[.7(W4>D:E1IZVM?NKMK5&]^S=X]TCX<_&KPKXDURSDNM)TR
MY$\\:1>8\(*G:ZKW,;$,%[[:]A_;S^.'AG]H*;P];^$8[S7+K06FN;[4UL)H
MQ%"ZD"++J#MW'=N8!1@88Y..3_:(?X?2> ]+;PJ--&H27"&'[&H#FW"G=YI'
MN0,'D$>E>A?L*_M7^"/@9\+-6T?Q%)>:3?-J+WQNH;4R#4(3&BB,E>A3:P ;
M _>GZ5]9PSG2S'"NG53I1FW\:U]WU?7\C\S\2N$_]7<VCB*,UBZM*,;>RDW!
MJ>KZ7;C?5+RNMCY;BD#H&#9!].13;L_Z+)RWW#V]JUO'6OVOBKQYKNJV-F=/
ML=4U">\M[7_GW220L%.._.2.Q)%9-T<VDGWON'^52U9V-H<SBG)<KLM.WE\M
MC^B#]D-L?\$2/#/]T?#=C_Y DKXA_P"#>;_@EA_PDV@>&?V@/B-81QZ7IUO%
M+X,TRZ&W[7,JC.J3*0 (T( A5LG>K2G $9/WM_P3\NM%LO\ @DC\.+CQ) ;K
MP[#X(B?4X?*,GFVXC?S 57YF^7/ Y-5_^"CVC>-/B;_P3&U2']G6[T^UCOM"
MM9=.CTN$(]_HAC0M!I[J5$+O;'$9 Z$ %"0R_'QK3C*=):<SU?8^I=.-HU7K
M9;'YI_\ !<[_ (*E+^UQX[G^%'@6_FF^&GA.]#ZI>#F/Q+J,3@J$/_/M;NN5
M)SYDJY "1J9/S^4_+U;\JBL_*%I&($,<*KM1-A3RP/X=IY7'(P>0<@\YJ7HO
M\5?38:A&C#DB?.UJTJLW.0RXN5MH&D9CM09/RY_2OWF_X)M?\$M='T?_ ()0
MZEX \;Z:L>M?&?3Y=6\1$HJ7-@;B/_0XT9D)CDMXA$P!R8YFE8<FORR_X)&?
ML=_\-I_MQ>&=#OH6E\)^%2/$GB,,,QRVL#KY=LPXW"><Q1LH.=A<C.TU^O'[
M5O\ P5FT7]G/_@I+\)?@C.VEG2_&43CQ->RN?,TF:YS%IBCD "69'WD_=10>
MXKR\TK2E-4:?35GI9;3BH.M/9Z'X$?$3X<ZY\&?B-X@\&^)HC!XB\(ZC-I&H
MKM*K)-$Q'FH& (CE4K*G'*2*>,X&0?F7^+\J_5G_ (.4OV(+?P_>:!\>?#NG
MK;K?7"Z'XQ:",CS9'V)97DF!CAD^SY[^?%V6ORG_ .^J]3"XA5Z:J+Y^IP8F
M@Z-1P/I?_@DI^W'X:_X)[_M97WCSQ;I7B36M'O/#-WHGV?0XX)+I)9;BTE20
MK-+$FS_1V4Y<'+# .#C]B_V'_P#@M)X _;_^-9\#>"? OQ0L[R'3I=4N]0U:
MUTV&QL((V5 9#'>R29>1T10D;$EB3A59A_.U<2K%;NSMLC4;F9NBXYR?I7[V
M?\$6/V5]-_8 _P""?-]\1_&QCT/7/'-H/%_B2:[S%_9FGQ0L]K;OD_*(X6>5
MMRJRO<R*P^0 >7FU&DH^T?Q/1'H994J-\B^%;GE7_!R_^V5_PB?PIT/X%Z+=
M;M2\;LNK^(U1OFM]*A?]W$3U7[1<*J\9W1PSCCJ/QI<_,WS-U)SLVY_#H*]
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M^*O!G@%=8C\3>)=0\'1>'[W7KFXFU"YC@L8M/749;=HFM-0FNKBXE2"'9&\
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MV?UHQ_LK1C_96@ Q_L_K1C_9_6C'^RM&/]E: #'^S^M&/]G]:,?[*T8_V5H
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MXJ_I4_X(]?\ **[]GO\ [$'2/_26.OYJ[8?Z1'POWNU?TJ?\$>O^45W[/?\
MV(.D?^DL=>-G7\./K^B/6RCXY>GZL^D****^</>&SAC"VW[V.*_'/X]_\&W?
MQ/\ BU^T)\1/&%C\0O =K8^,_%FK^(;:WN+>[::WBO+Z>Y2-RJXW*LH4XR,@
M\D5^QQ&10%Q6]#$5*+YJ;,:V'A55IH_$?_B%_P#BS_T4GX<_^ M[_P#$T?\
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M]_P#^S*';\6?B/\ \0P'Q8_Z*5\.?_ :]_\ B:/^(8#XL?\ 12OAS_X#7O\
M\37[<44?VIB>_P" ?V;0[?BS\1_^(7_XL_\ 12?AS_X"WO\ \30?^#7_ .+'
M_12OAS_X"WO_ ,37[<44?VIB>_X!_9M#M^+/Q'_XA@/BQ_T4KX<_^ U[_P#$
MT#_@V ^+'_12?AS_ . M[_\ $U^W%%']J8GO^ ?V;0[?BS\1S_P:_P#Q8Q_R
M4KX<_P#@+>__ !-'_$,!\6/^BE?#G_P&O?\ XFOVXHH_M3$]_P  _LVAV_%G
MXCC_ (-@/BQ_T4KX<_\ @+>__$T?\0O_ ,6?^BD_#G_P%O?_ (FOVXHH_M3$
M]_P#^S:';\6?B.?^#8#XL9_Y*5\.?_ :]_\ B:/^(8#XL?\ 12OAS_X#7O\
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M/?\  /[-H=OQ9^(Y_P"#7_XLX_Y*3\.?_ 6]_P#B:/\ B& ^+'_12OAS_P"
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8@8KGKXNK6_B,Z*.%ITM8(****YSH/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
